menu search

CGNSF / Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform

Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform
The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - Cognetivity Neurosciences Ltd.  (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB)  ("the Company" or "Cognetivity") is pleased to note Eli Lilly & Co.'s results for its experimental drug for Alzheimer's disease, which demonstrated slowing the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. Read More
Posted: May 9 2023, 09:23
Author Name: Newsfile Corp
Views: 101914

CGNSF News  

Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform

By Newsfile Corp
May 9, 2023

Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform

The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage Vancouver, British Columbia--(Newsfile more_horizontal


Search within

Pages Search Results: